Related Experiment Videos
Cloxacillin versus pristinamycin for superficial pyodermas: a randomized, open-label, non-inferiority study
O Chosidow1, P Bernard, P Berbis
1Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris and Université Paris-VI, France. olivier.chosidow@psl.ap-hop-paris.fr
Dermatology (Basel, Switzerland)
|June 9, 2005
Summary
Oral cloxacillin and pristinamycin demonstrate comparable efficacy in treating superficial pyodermas. Cloxacillin offers a safe alternative with a significantly lower discontinuation rate in out-patients.
Area of Science:
- Dermatology
- Infectious Diseases
- Pharmacology
Background:
- Superficial pyodermas necessitate systemic antibiotic treatment.
- Previous studies indicated similar cure rates for oxacillin and pristinamycin, but lacked robust non-inferiority trial design.
Purpose of the Study:
- To evaluate and compare the efficacy and safety of oral cloxacillin against pristinamycin for superficial pyoderma treatment.
- To establish cloxacillin as a potential non-inferior alternative to pristinamycin.
Main Methods:
- Conducted a multicenter, parallel-group, open-label, randomized non-inferiority trial.
- Included 334 out-patients treated with either oral cloxacillin or pristinamycin at 2 g/day.
- Assessed cure rates at day 14 as the primary efficacy endpoint.
Main Results:
- Intent-to-treat analysis showed cure rates of 80.7% for cloxacillin and 82.8% for pristinamycin.
- The observed difference (-2.1%) met the non-inferiority margin (-15%).
- Significantly fewer patients discontinued pristinamycin (9/163) compared to cloxacillin (1/171; p=0.01).
Conclusions:
- Oral cloxacillin is a viable and effective alternative to pristinamycin for treating superficial pyodermas in out-patients.
- Cloxacillin demonstrated comparable efficacy with improved safety due to a lower discontinuation rate.